Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

• Status: Completed
• Trial end date: 2018-01-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• ≥18 years old, diagnosed with persistent or chronic ITP

Exclusion Criteria:

• Secondary immune thrombocytopenia

• Drug induced thrombocytopenia